Base Year
Historical Year
Forecast Year
The India diabetes market size was valued at INR 316 billion in 2023, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16% during the forecast period of 2024-2032, with the values likely to rise from INR 366.56 billion in 2024 to INR 1201.74 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Diabetes is a condition where the body cannot use the insulin produced effectively or the pancreas does not produce enough insulin at all. Insulin is a hormone produced to regulate glucose in the body. There are two categories of diabetes, type 1 and type 2. Type 1 diabetes is based on the amount of insulin produced by the body and type 2 diabetes is based on the management of insulin by the body. Common symptoms include frequent thirst, blurred vision, fatigue, unintentional weight loss and constant urge to urinate.
The diabetes incidence rate in India stands at around 10.1 crores in 2023. The India diabetes market value is driven by the rising awareness among the patients about the symptoms of diabetes, and its ill effects on health, which has majorly intensified the diagnosis and increased the drug treatment rates in the country.
Rapid urbanization and developing healthcare infrastructure are also aiding the industry growth of diabetes in India. In addition to this, extending pharmaceutical contract manufacturing, low-cost drug production, and the introduction of advanced technologies have further accelerated the growth of diabetes market in India. In July 2023, the Indian Institute of Technology (IIT) Bhilai and Shiv Nadar University revealed “smart insulin”, which contains an extended period of insulin release that lasts up to 2 days, far greater than the average 12-hour duration of regular insulin.
To meet the high India diabetes market demand, leading health platforms for diabetes like the BeatO App have announced their physical clinic collaborations. After launching 5 clinics across Delhi-NCR, the company visions to spread across Uttar Pradesh, Madhya Pradesh, Rajasthan, Gujarat, and Odisha in the next 6 months. Akums Drugs and Pharmaceuticals Limited also received approval for its triple combination diabetes treatment which includes Sitagliptin 100, Pioglitazone 15 and Metformin 1000/500. Therefore, the market is expected to witness significant growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Type
Market Breakup by Treatment Type
Market Breakup by Doses Form
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The India diabetes market growth is driven by the launch of programs like National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD), which has been launched by the government of India and works on delivering glucometer and drugs for diabetes to the patients. As a part of this program, the region is also experiencing the set-up of new district clinics and community health centers to promote early diagnosis and prevention of the condition. Movements like Fit India, Khelo India and several yoga related activities are also promoted by the Ministry of AYUSH to promote physical activity in all generations.
Moreover, the increasing partnerships amongst private and state-owned entities will also contribute significantly to the India diabetes market share and deliver better solutions to diabetic and pre-diabetic patients. Promotional activities to eat healthy are also advocated by prominent institutions like FSSAI. Eat Right Initiative, Safe and Nutritious Food at Home and ‘Aaj se thoda kum’ awareness initiatives are some of the prime examples. Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the masses are also set to receive generic medicines like insulin at affordable prices.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment Type |
|
| Breakup by Doses Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about INR 316 billion in 2023, driven by rising incidence of diabetes cases in the region.
The market is anticipated to grow at a CAGR of 16% during the forecast period of 2024-2032, likely to reach a market value of INR 1201.74 billion by 2032.
The market demand is driven by increasing government and private institution driven awareness initiatives among the patients about the symptoms and treatment of diabetes.
The current market trend is driven by the advent of new technical inventions. In July 2023, IIT Bhilai and Shiv Nadar University collaborated to develop a “smart insulin”.
Diabetes can be divided into type 1 diabetes and type 2 diabetes.
Treatment types include insulin-based and non-insulin-based, among others.
Dose forms include tablets and capsules, injections, creams and gels, among others.
Major distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.
Major end users include hospitals, speciality clinics, and homecare settings, among others.
The route of administration can be oral or parenteral.
Key players involved in the market are Sun Pharmaceutical Industries Ltd., Biocon Limited, Dr. Reddy's Laboratories Ltd., Novo Nordisk India Pvt. Ltd., Sanofi India Limited, Eli Lilly and Company (India) Pvt. Ltd., Johnson & Johnson Private Limited, Abbott India Limited, Glenmark Pharmaceuticals Ltd., AstraZeneca Pharma India Limited, Lupin Limited, Torrent Pharmaceuticals Ltd., Merck Limited, Cadila Healthcare Limited and Wockhardt Limited.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share